Avecho Biotechnology (ASX: AVE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Avecho Biotechnology Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Avecho Biotechnology (ASX: AVE)
Latest News
Healthcare Shares
Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in
Share Market News
Avecho (ASX:AVE) share price rockets 83% on milestone announcement
AVE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Avecho Biotechnology
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. It operates through the following business segments: Production and Personal Care; Human Health; and All Other. The Production and Personal Care segment manufactures and sells TPM and Vital ET. The Human Health segment covers delivery of drugs through gels, injectables, and patches. The All Other segments involves the BioElixia division. The company was founded on June 19, 1992 and is headquartered in Clayton, Australia.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 25 May 2026 | Matthew McNamara | Expiry | 1,584,650 | $19,015 |
Options expired.
|
| 06 May 2026 | Gregory (Greg) Collier | Exercise | 800,000 | $9,600 |
Exercise of options.
|
| 06 May 2026 | Gregory (Greg) Collier | Issued | 800,000 | $9,600 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Gregory (Greg) Collier | Non-Executive ChairmanNon-Executive Director | Apr 2019 |
Dr Collier has more than 25 years of experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and M&A activities, and he has taken a drug from discovery through to regulatory approval.
|
| Dr Ross Murdoch | Non-Executive Director | Apr 2015 |
Dr Murdoch has over 30 years of experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses.
|
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | Apr 2024 |
Ms Connell has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, as well as having worked in healthcare and lifesciences executive search and management consulting with Korn Ferry.
|
| Dr Paul Gavin | Chief Executive Officer | May 2020 |
-
|
| Ms Naomi Lawrie | Company Secretary | May 2026 |
-
|
| Paul Gavin | Chief Executive Officer |
-
|
|
| Roksan Libinaki | Chief Operating Officer |
-
|
|
| Naomi Lawrie | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Paradyce Pty Ltd <The Paradyce A/C> | 349,133,188 | 9.50% |
| Ms Chunyan Niu | 188,700,000 | 5.14% |
| Rosscope Pty Ltd <Ross Copeland Family A/C> | 89,973,986 | 2.45% |
| HSBC Custody Nominees (Australia) Limited | 60,723,184 | 1.65% |
| Berne No 132 Nominees Pty Ltd <791994 A/C> | 50,000,000 | 1.36% |
| Mr Joshua Gordon | 50,000,000 | 1.36% |
| Mr Brandon Armon Batagol | 44,532,406 | 1.21% |
| Jawess Pty Ltd <Kent Family Super Fund A/C> | 42,814,606 | 1.17% |
| BNP Paribas Norns Pty Ltd | 39,471,473 | 1.07% |
| Greensea Investments Pty Ltd | 35,000,000 | 0.95% |
| Ice Cold Investments Pty Ltd <G & J Brown Super Fund A/C> | 35,000,000 | 0.95% |
| Dr Maurice Arthur Trewhella and Mrs Elizabeth Trewhella <Simpetejen Super Fund A/C> | 30,000,000 | 0.82% |
| Servbond Pty Limited <Servbond Pty Ltd S/F A/C> | 29,615,982 | 0.81% |
| Mr Andrew James Caddy | 28,000,000 | 0.76% |
| Dr Stephen Dennis Gipps | 25,500,000 | 0.69% |
| King Corporate Pty Ltd | 25,333,333 | 0.69% |
| Mr David Segal | 25,000,000 | 0.68% |
| Citicorp Nominees Pty Limited | 24,646,941 | 0.67% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 24,516,599 | 0.67% |
| Zico Investments Pty Ltd | 24,000,000 | 0.66% |
